文献速递淋巴瘤

套细胞淋巴瘤的一线治疗:当临床试验数据与真实世界数据碰撞

Frontline Therapy in Mantle Cell Lymphoma: When Clinical Trial and Real-World Data Collide.
PubMed 文献 · J Clin Oncol · 2022-09-28

本文以一位73岁女性套细胞淋巴瘤患者经苯达莫司汀联合利妥昔单抗诱导达缓解的病例为引,综述一线治疗选择文献,重点讨论诱导方案选择及自体移植和利妥昔单抗维持的作用;文献主要包括前瞻性2期和3期临床试验,以及Martin等新近发表的大样本回顾性真实世界队列分析;部分真实世界证据与前瞻性试验数据不一致,例如苯达莫司汀联合利妥昔单抗诱导后利妥昔单抗维持的作用。

要点

  • 套细胞淋巴瘤一线治疗选择众多,诱导方案选择是临床难点。
  • 文献主体为前瞻性2期和3期临床试验,新增大样本回顾性真实世界队列证据。
  • 苯达莫司汀联合利妥昔单抗诱导后利妥昔单抗维持的作用,真实世界证据与前瞻性试验数据存在不一致。

核心结论

  • 套细胞淋巴瘤一线治疗选择众多,临床决策需综合前瞻性临床试验与不断积累的真实世界证据;部分真实世界证据与前瞻性试验数据不一致,例如苯达莫司汀联合利妥昔单抗诱导后利妥昔单抗维持的作用。

研究设计与样本

  • 肿瘤学大查房系列文章:先呈现一例73岁女性套细胞淋巴瘤病例,随后描述诊断与管理挑战、综述相关文献,并总结作者建议的管理方法。
  • 相关文献主要包括前瞻性2期和3期临床试验,并纳入不断增多的大样本回顾性真实世界队列,如Martin等的新分析。

主要发现

  • 一例73岁女性套细胞淋巴瘤患者经苯达莫司汀联合利妥昔单抗治疗达到缓解。
  • 部分真实世界证据与前瞻性临床试验数据不一致,例如关于苯达莫司汀联合利妥昔单抗诱导后利妥昔单抗维持的作用。

临床怎么用

  • 作者希望将重要的新真实世界数据置于不断变化的治疗格局中,以帮助临床医生为套细胞淋巴瘤患者选择一线治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.A large number of frontline treatment options exist for mantle cell lymphoma (MCL), making selection of therapy a challenge for the clinician. In this Oncology Grand Rounds article, the case of a 73-year-old woman with MCL who attained remission with bendamustine and rituximab is presented. The relevant literature regarding frontline therapy is then reviewed, with particular focus on selection of induction regimen and the potential roles for autologous transplantation and/or rituximab maintenance. This literature primarily consists of prospective phase 2 and phase 3 clinical trials; however, added to this literature now is a growing body of large retrospective real-world cohorts, such as the new analysis by Martin et al,35 the manuscript that accompanies this Oncology Grand Rounds article. In some cases, the real-world evidence is at odds with data from prospective clinical trials, such as regarding the role of rituximab maintenance after bendamustine plus rituximab induction. These important new real-world data are put into context of an ever-changing treatment landscape, in hopes of aiding clinicians in frontline treatment selection for patients with MCL.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Fenske TS. Frontline Therapy in Mantle Cell Lymphoma: When Clinical Trial and Real-World Data Collide. J Clin Oncol. 2022. PMID: 36170622. doi:10.1200/JCO.22.01661

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。